XNAS · Healthcare · Biotechnology
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.26 | -0.21 | +19.23% | $0 | ✅ Beat | -0.19% | +4.46% | — |
| 2026-03-06 | Q4 2025 | -0.31 | -0.18 | +41.94% | $0 | ✅ Beat | -1.20% | -5.25% | +1.31% |
| 2025-11-12 |
| Q3 2025 |
| -0.38 |
| -0.38 |
| +0.00% |
| $0 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.40 | -0.40 | +0.00% | $0 | ➖ Inline | +0.93% | +6.52% | +163.66% |
| 2025-03-20 | Q4 2024 | -0.47 | -0.58 | -23.40% | $0 | ❌ Miss | +9.09% | +0.61% | -16.36% |
| 2024-11-13 | Q3 2024 | -0.55 | -0.49 | +10.91% | $0 | ✅ Beat | +13.45% | +19.30% | -4.39% |
| 2024-08-06 | Q2 2024 | -0.52 | -0.47 | +9.62% | $0 | ✅ Beat | -8.06% | -8.06% | -4.03% |
| 2024-05-07 | Q1 2024 | -0.46 | -0.49 | -6.52% | $0 | ❌ Miss | +4.49% | +2.56% | -9.62% |
Showing last 8 quarters.